Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

55.88 -2.04 (-3.52%)
Streaming Delayed Price Updated: 3:43 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Appoints Michael McDonnell to Board of Directors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Science Day Highlights Expanding Potential of mRNA Platform
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna to Host Investor Event - Science Day
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Via ACCESS Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
From BioMedWire
Via GlobeNewswire
News headline image
Moderna to Present at Upcoming Conference in June 2026
Via ACCESS Newswire
News headline image
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
Via ACCESS Newswire
News headline image
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Via ACCESS Newswire
News headline image
Moderna Recognized by TIME as One of the World's Most Impactful Companies
Via ACCESS Newswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
Via Investor Brand Network
Topics Intellectual Property
News headline image
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Via ACCESS Newswire
News headline image
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
Via ACCESS Newswire
News headline image
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Via ACCESS Newswire
News headline image
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Via ACCESS Newswire
News headline image
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
News headline image
Moderna to Present at Upcoming Conferences in May 2026
Via ACCESS Newswire
News headline image
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
Via ACCESS Newswire
News headline image
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
Via ACCESS Newswire
News headline image
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
Via ACCESS Newswire
News headline image
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Via ACCESS Newswire
News headline image
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.